SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Lingjian Morphology Diagnostics Transforming Clinical Laboratory Practices
Lingjian Morphology Diagnostics transforms microscopic analysis in clinical laboratories by uniting image interpretation, cell classification, morphological description, target localization, and natural language interaction within a single vision-language architecture. Developed to overcome pract...
Joint Scientific Consultation EU Strategies for Medical Device Companies
The EU Joint Scientific Consultation gives medical device developers a voluntary route to obtain targeted feedback on clinical evidence plans well before formal Joint Clinical Assessment and national reimbursement decisions. Manufacturers of select high-risk technologies can align their developme...
Insights on EU Joint Clinical Assessment for High-Risk Medical Devices
EU Joint Clinical Assessment is a distinct, harmonised process that operates separately from CE marking. It produces comparative clinical evidence on selected high-risk devices to support more consistent national reimbursement decisions across EU member states. Insights from the